Answers are grounded in this paper and cite their sources.
Reviews gender disparities in thrombosis and hemostasis care and research, highlighting the urgent need for sex-tailored therapies and equitable representation for female hematologists.
Gender biases and inequities contribute to poorer clinical outcomes for female patients, and negatively affect their female caregivers. The McKinsey Health Institute recently estimated the economic burden and opportunity cost to be US $1 trillion for not closing this women's health gap.1 Structural gender biases undermine current clinical care and manifest in a multitude of ways,2 in the setting of thrombosis and hemostasis we have examples of dismissing clinical symptoms to gaps in understanding gender-specific presentations of common diseases in women, such as acute myocardial infarction, or uniquely female conditions like hypermenorrhea and associated iron-deficiency anemia.3 Stereotyping and underrepresentation of female providers further compound the problem as they can erode patient trust which has been linked to care avoidance.4 These systemic challenges collectively can contribute to delayed diagnoses, inadequate symptom relief, suboptimal treatment, and, ultimately, poorer clinical outcomes. Clinical research suffers as much as any area from gender bias. In a world where most research funding is used to address diseases of men, and thus the majority of recruited patients are men, women's issues have been underfunded for decades.5 The most extreme example is the dearth of clinical trials in pregnancy, particularly notable in the field of venous thromboembolism (VTE). Despite VTE remaining the number one cause of death in pregnancy in high-income countries, there have never been any randomized clinical trials of preventing or treating VTE.6, 7 All the use of anticoagulants in pregnancy is extrapolated from data in non-pregnant patients. The inevitable consequences of the lack of clinical trials in pregnancy are that there is a lack of evidence-based guidelines in pregnancy and the lack of evidence about medication use in pregnancy puts mothers and babies at risk. The problem is long-standing as pregnant and lactating women have been traditionally excluded from clinical trials. For example, in the USA only with the adoption of the New Common Rule in 2018, pregnant women are no longer considered as a vulnerable population under 45 CFR 46.111; nonetheless, the considerations under 45 CFR 46.204 still apply and pregnant women may only be included in research approvable by an Institutional Review Board (IRB) under very restrictive conditions.8 At a global level, it is important to point out that non-communicable diseases (NCDs) cause 74% of deaths among both men and women worldwide in all. Low- and middle-income countries are disproportionately affected, accounting for 77% of all NCD deaths, and NCD-related mortality is on the rise.9, 10 The largest cause of death due to NCDs is cardiovascular diseases causing 19.9 million deaths. Indeed, thrombosis is the major final common pathway in this group, and itself causes one in four deaths.11 These deaths include myocardial infarction, stroke, peripheral vascular disease, and VTE. Gender biases also affect female physicians. Despite comprising 40%–49% of first-year fellows in hematology/oncology, women's representation in the practicing academic workforce falls below 40%. While this is not as severe as in other areas of medicine, it still matters. This disparity is particularly pronounced in leadership positions; for instance, in its first 50 years only four of the presidents of the American Society of Hematology were women. Additionally, women in hematology are less likely to receive recognition and awards for their contributions to education, research, and clinical practice. This disparity extends to salary gaps, beginning in residency and persisting into senior faculty roles.12-14 The problem is compounded by the knowledge that most women doctors continue to experience sexism and gender bias at work in their day-to-day dealing with patients and other healthcare professionals. In a UK survey, women doctors felt sexism was an issue in limiting career advancement, and a minority continue to complain about unwanted physical contact at the workplace.15 In 2023, we helped organize a seminar titled “Maintaining Hemostasis in Women: Breakthroughs and Ongoing Challenges” at the annual ISTH meeting in Montreal. Despite its scheduling during a competitive timeslot, the seminar attracted a substantial audience, highlighting the urgent need for focused attention on this subject. Particularly noteworthy was the fact that the seminar was led and executed entirely by an all-female team, consisting of experts from diverse clinical backgrounds and at various career stages. Their combined expertise and passion served as catalyst for the creation of this supplementary issue, where they and their teams share their latest research to deepen our understanding and progress the themes discussed. To us, this special edition is a meaningful and significant investment—an exclusive platform dedicated to female-centric clinical research issues, with the aim of amplifying the visibility and contributions of pioneering female physician scientists. The selected topics span a broad spectrum, ranging from investigating aspirin response in patients with peripheral artery disease (PAD) to revealing new diagnostic insights for the personalized treatment of postpartum hemorrhage. Additionally, they delve into understanding the prothrombotic state in patients undergoing treatment for gynecological cancers and exploring gender differences in trauma-induced coagulopathy. Among the featured studies, Suarez Ferreira et al. present an insightful investigation into platelet function differences between men and women with PAD on aspirin therapy post-revascularization. Their prospective, observational study utilizes thromboelastography with platelet mapping to delineate sex-specific responses to aspirin. Notably, women demonstrated significantly greater thrombotic propensity and lower platelet inhibition compared to men, indicating a potential need for tailored antiplatelet strategies in female PAD patients.16 Rigouzzo et al. contribute an article focusing on the early and rapid assessment of hemostasis in postpartum hemorrhage (PPH). Their research underscores the importance of timely characterization of coagulopathy and estimation of bleeding severity to improve outcomes in PPH cases. Utilizing point-of-care viscoelastic hemostatic assays, the study demonstrates the efficacy of rapid assessment of hemostatic disorders and low fibrinogen levels, facilitating guided fibrinogen replacement.17 Tera et al. provide valuable insights into VTE risk assessment in women undergoing chemotherapy for cancer. Their work assesses the coagulation profile of female cancer patients, aiming to improve upon current risk assessment models such as the Khorana score (KS). The results reveal hypercoagulability in a significant proportion of patients, with viscoelastic parameters showing potential correlations with KS and actual VTE events.18 The review by Coleman et al. elucidates gender-specific differences and polymorphisms influencing the development of trauma-induced coagulopathy, one of the leading preventable causes of death. The work highlights mechanisms underlying sex dimorphisms in coagulation and explores their implications for tailored resuscitation of trauma patients.19 We trust that readers will find the compiled work thought-provoking. While none of the studies provide definitive evidence for suggested changes in treatment or guidelines, they collectively emphasize the importance of gaining a more nuanced understanding of the functional coagulation state of individual patients, highlighting gender-specific differences, and underscoring the imperative of tailoring interventions accordingly. This special edition should be seen as a contribution to the journey toward deeper insights into thrombosis and hemostasis in female patients. We aspire to inspire and amplify female voices, fostering greater dialogue and recognition for their invaluable contributions and those of their teams.
No takes yet. Share an insight, caveat, or question.
Hartmann et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: